‘French Spiderman’ barred from climbing UK buildings

SHARE ‘French Spiderman’ barred from climbing UK buildings
ap18298479485950.jpg

Urban climber dubbed the French Spiderman, Alain Robert celebrates after he scaled the outside of Heron Tower building in the City of London, Thursday, Oct. 25, 2018. Heron Tower is over 200 metres high. | Frank Augstein/Associated Press

LONDON — French urban climber Alain Robert has been banned from climbing any building in Britain after scaling one of London’s tallest skyscrapers without ropes — and without permission.

Robert climbed the 662-foot (202-meter) Heron Tower on Thursday as police cordoned off the building, closed roads and ushered spectators away.

He was arrested after the climb and appeared in a London court on Friday. Robert pleaded guilty to causing a public nuisance and received a 20-week suspended sentence and a 5,500 pound ($7,000) fine. He was also barred from climbing all buildings in Britain “until further notice.”

The 56-year-old daredevil, known as “the French Spiderman,” has climbed many of the world’s tallest structures.

Before Thursday’s climb, he told reporters “I fully feel alive when my life is at stake.”

The Latest
The aim is to give students who might not initially see themselves going to a four-year school a boost that might help them eventually get a bachelor’s degree, as few two-year students do now.
Girls says the man is angry that she stood up for her mom in a disagreement about the couple’s sex and drinking habits.
Trout Unlimited’s Trout In The Classroom teaches young students about fish and the aquatic environment, capped by a day trip to get all wet.
Businesses and neighborhood associations in River North and nearby want the city to end the dining program because of traffic congestion, delays to first responders and other headaches caused by closing off a major street artery, a local restaurant executive writes.
High doses become routine patient care even when they make patients so ill that they skip doses or stop taking the drugs. “There’s a gap in FDA’s authority that results in patients getting excess doses of a drug at excess costs,” says Dr. Mark Ratain, a University of Chicago oncologist.